Magnera swings to Q4 operating loss due to impairment charges
MAGN•Magnera reported a $90 million operating loss in Q4, including $106 million in impairment charges, while net sales rose 1% year over year to $851 million and adjusted EBITDA increased 8% to $97 million. The company forecast fiscal 2027 adjusted EBITDA of $390 million to $410 million.
1. Quarterly results
Magnera’s Q4 net sales rose 1% year over year to $851 million, and adjusted EBITDA grew 8% to $97 million. The company posted a $90 million operating loss, including $106 million in impairment charges. Adjusted EBITDA was below the $98.11 million consensus estimate from one analyst.
2. Sales and costs
Higher selling prices, largely reflecting the pass-through of increased raw material costs, drove sales growth. Organic volume fell 4%, mainly because of softer healthcare demand in the Americas and continued market softness in Europe. Improved adjusted EBITDA was mainly driven by a favorable price-cost spread.
3. Fiscal 2027 outlook
Magnera expects fiscal 2027 adjusted EBITDA of $390 million to $410 million, free cash flow of $110 million to $130 million, and cash flow from operations of $195 million to $215 million.




